Merck!!!
- Thread starter wareagle
- Start date
Dollar cost average. I'd wait until Monday though. Maybe a buy at 345PM, right before the bell Friday.
You'll be fine long run, that's for sure. Lots of folks retiring. Hang in there.
Good luck.
nole
You'll be fine long run, that's for sure. Lots of folks retiring. Hang in there.
Good luck.
nole
oh my, here come the lawsuits!!!
Merck is going down....never to produce a drug again......
I can see it now:"If you have had any kind of illness while taking Vioxx please call us so we can help you. You may be entitled to millions of dollars........."
Merck is going down....never to produce a drug again......
I can see it now:"If you have had any kind of illness while taking Vioxx please call us so we can help you. You may be entitled to millions of dollars........."
You'll notice numerous attorneys were way ahead of the news announced today. Seems to have been a supposed health risk many months back. The sharks are circling...
They mentioned a couple of things on this story on local radio...
The government may step in and bail them out with a bucket of money :scared
They will have to come out with a new drug by themselves or by buying a smaller company that has one.
The government may step in and bail them out with a bucket of money :scared
They will have to come out with a new drug by themselves or by buying a smaller company that has one.
DO you think lawsuits will be coming....
http://www.motleyrice.com/pharmaceutical_drugs/pharmaceutical_drugs_vioxx.html
I am sure this was up within minutes...
D.G.
http://www.motleyrice.com/pharmaceutical_drugs/pharmaceutical_drugs_vioxx.html
I am sure this was up within minutes...
D.G.
Even fraudulent securities dating from last year to present over this...
Press Release Source: Wolf Haldenstein Adler Freeman & Herz LLP
Wolf Haldenstein Commences Securities Fraud Class Action Against Merck & Co., Inc., and Certain Officers of the Company
Friday October 1, 11:47 am ET
NEW YORK, Oct. 1 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP commenced a class action lawsuit in the United States District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Merck & Co., Inc. securities, including common stock ("Merck" or the "Company") (NYSE: MRK - News), between October 30, 2003 and September 29, 2004, inclusive (the "Class Period") and who suffered damages.
ADVERTISEMENT
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Gregory M. Nespole, Esq. at Wolf Haldenstein. A copy of the complaint filed against Merck can be read and downloaded from the Wolf Haldenstein web page at http://www.whafh.com.
The complaint alleges that Merck failed to disclose material information during the Class Period concerning the safety profile of its arthritis drug Vioxx, and that a growing body of evidence demonstrated that patients who used the drug for more than 18 months were exposed to an increased risk of heart attack.
Specifically, on September 30, 2004, the Company announced that it was immediately withdrawing Vioxx from world markets after a data safety monitoring board, overseeing a long-term study of the drug, recommended that the study be halted because of an increased risk of serious cardiovascular events among members of the study group. The Company's sudden decision to withdraw Vioxx was in stark contrast to its prior public announcements during the Class Period touting the safety of Vioxx and other public disclosures by the Company and its representatives that specifically refuted criticism of the drug lodged by respected clinicians.
Indeed, the Company's shocking withdrawal of Vioxx on September 30, 2004, came only one month after the Company issued a strongly worded press release refuting reputable clinicians' criticisms of Vioxx and its safety profile and on the heels of the Company obtaining approval to market the drug for the treatment of juvenile arthritis and migraines.
In addition to frightening millions of people who were misled and used Vioxx despite these serious risks, the announcement caused the Company's common stock to plummet during September 30, 2004 trading by approximately 25%, or $12 per share. The resulting market capitalization loss was a staggering $26 billion.
Plaintiff seeks to recover damages on behalf of all class members who purchased Merck securities, including common stock, during the Class Period. Plaintiff is represented by the law firm of Wolf Haldenstein Adler Freeman & Herz LLP (http://www.whafh.com).
The Wolf Haldenstein firm has a full service commercial practice consisting of approximately 60 attorneys based in New York City, San Diego, New Jersey, and Chicago. The firm's litigation department is recognized by courts throughout the country as highly experienced and skilled in complex litigation, particularly with respect to federal securities laws, class actions and shareholder litigation. The firm's qualifications repeatedly receive very favorable judicial recognition. The firm has achieved recoveries of $2 billion on behalf of investors and shareholders.
If you purchased Merck securities (including shares of its common stock, debt instruments, call options, and/or sold put options) you have until November 30, 2004 to participate in the case and ask the Court to appoint you as one of the lead plaintiffs for the Class. In order to serve as lead plaintiff, you must meet certain legal requirements. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as "lead plaintiff." Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Wolf Haldenstein, or other counsel of your choice, to serve as your counsel in this action.
If you wish to discuss this action or have any questions, please contact Wolf Haldenstein Adler Freeman & Herz LLP at 270 Madison Avenue, New York, New York 10016, by telephone at 212.545.4600 or 800.575.0735 (Gregory M. Nespole, Esq.), via e-mail at classmember@whafh.com, nespole@whafh.com, or you may visit our web site located at http://www.whafh.com.
Press Release Source: Wolf Haldenstein Adler Freeman & Herz LLP
Wolf Haldenstein Commences Securities Fraud Class Action Against Merck & Co., Inc., and Certain Officers of the Company
Friday October 1, 11:47 am ET
NEW YORK, Oct. 1 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP commenced a class action lawsuit in the United States District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Merck & Co., Inc. securities, including common stock ("Merck" or the "Company") (NYSE: MRK - News), between October 30, 2003 and September 29, 2004, inclusive (the "Class Period") and who suffered damages.
ADVERTISEMENT
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Gregory M. Nespole, Esq. at Wolf Haldenstein. A copy of the complaint filed against Merck can be read and downloaded from the Wolf Haldenstein web page at http://www.whafh.com.
The complaint alleges that Merck failed to disclose material information during the Class Period concerning the safety profile of its arthritis drug Vioxx, and that a growing body of evidence demonstrated that patients who used the drug for more than 18 months were exposed to an increased risk of heart attack.
Specifically, on September 30, 2004, the Company announced that it was immediately withdrawing Vioxx from world markets after a data safety monitoring board, overseeing a long-term study of the drug, recommended that the study be halted because of an increased risk of serious cardiovascular events among members of the study group. The Company's sudden decision to withdraw Vioxx was in stark contrast to its prior public announcements during the Class Period touting the safety of Vioxx and other public disclosures by the Company and its representatives that specifically refuted criticism of the drug lodged by respected clinicians.
Indeed, the Company's shocking withdrawal of Vioxx on September 30, 2004, came only one month after the Company issued a strongly worded press release refuting reputable clinicians' criticisms of Vioxx and its safety profile and on the heels of the Company obtaining approval to market the drug for the treatment of juvenile arthritis and migraines.
In addition to frightening millions of people who were misled and used Vioxx despite these serious risks, the announcement caused the Company's common stock to plummet during September 30, 2004 trading by approximately 25%, or $12 per share. The resulting market capitalization loss was a staggering $26 billion.
Plaintiff seeks to recover damages on behalf of all class members who purchased Merck securities, including common stock, during the Class Period. Plaintiff is represented by the law firm of Wolf Haldenstein Adler Freeman & Herz LLP (http://www.whafh.com).
The Wolf Haldenstein firm has a full service commercial practice consisting of approximately 60 attorneys based in New York City, San Diego, New Jersey, and Chicago. The firm's litigation department is recognized by courts throughout the country as highly experienced and skilled in complex litigation, particularly with respect to federal securities laws, class actions and shareholder litigation. The firm's qualifications repeatedly receive very favorable judicial recognition. The firm has achieved recoveries of $2 billion on behalf of investors and shareholders.
If you purchased Merck securities (including shares of its common stock, debt instruments, call options, and/or sold put options) you have until November 30, 2004 to participate in the case and ask the Court to appoint you as one of the lead plaintiffs for the Class. In order to serve as lead plaintiff, you must meet certain legal requirements. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as "lead plaintiff." Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Wolf Haldenstein, or other counsel of your choice, to serve as your counsel in this action.
If you wish to discuss this action or have any questions, please contact Wolf Haldenstein Adler Freeman & Herz LLP at 270 Madison Avenue, New York, New York 10016, by telephone at 212.545.4600 or 800.575.0735 (Gregory M. Nespole, Esq.), via e-mail at classmember@whafh.com, nespole@whafh.com, or you may visit our web site located at http://www.whafh.com.
